Is Testosterone For Menopausal Women Evidence-based?

What should clinicians know first?

As of October 17, 2026, the only evidence-based indication for testosterone in women, per the 2019 Global Consensus Position Statement, is postmenopausal hypoactive sexual desire disorder (HSDD) after a formal biopsychosocial assessment, at doses that keep blood levels in the physiologic female range. The 2019 Islam et al. meta-analysis (36 RCTs, 8,480 participants) found improved sexual function with testosterone versus placebo or comparator in postmenopausal women, with a preferred non-oral route for a neutral lipid profile. There is no FDA-approved testosterone product for women in the United States. FDA is accepting comments on docket FDA-2026-N-5479 through 11:59 p.m. ET on October 19, 2026.

This is for MDs, DOs, NPs, and PAs in longevity, functional, and hormone clinics who prescribe off-label testosterone to women, and for patients asking what the evidence supports. FDA's September 17, 2026 public workshop on testosterone use in menopausal women has an open comment docket through October 19, 2026.

What is the U.S. regulatory status right now?

FDA's Federal Register notice (2026-16829) and workshop page both state that, unlike estrogen-containing products, there are no FDA-approved indications for testosterone therapy for menopausal women. The same notice says off-label use in women nearing or after menopause has increased over the past decade, that testosterone is currently approved for HSDD in women in Australia, New Zealand, the UK, and South Africa, and that long-term safety data beyond 24 months are limited, particularly for cardiovascular and breast cancer risks.

FDA's workshop framed the knowledge gaps it wants addressed: the role of testosterone in sexual function, cognition, mood, and musculoskeletal health; challenges in measuring and interpreting testosterone levels; and the absence of long-term safety data, especially for cardiovascular and breast cancer risks. The workshop was held September 17, 2026. The comment period that followed is still open until October 19.

What does the evidence support for HSDD?

The Global Consensus Position Statement (Davis et al., 2019), published in JCEM and Climacteric and available in full text via PMC6821450, states that the only evidence-based indication for testosterone in women is treatment of postmenopausal women diagnosed with HSDD after formal biopsychosocial assessment. It reports a beneficial effect on sexual function at doses that approximate physiologic premenopausal testosterone concentrations, with Level I, Grade A language for that sexual-function finding in the consensus text.

Islam et al. (2019) pooled 46 reports of 36 randomized controlled trials with 8,480 participants. Versus placebo or a comparator (for example estrogen with or without progestogen), testosterone increased satisfactory sexual event frequency (mean difference 0.85, 95% CI 0.52 to 1.18), sexual desire (standardized mean difference 0.36, 95% CI 0.22 to 0.50), pleasure, arousal, orgasm, responsiveness, and self-image, and reduced sexual concerns and distress in postmenopausal women. Oral testosterone raised LDL-cholesterol and lowered total cholesterol, HDL-cholesterol, and triglycerides; those lipid shifts were not seen with non-oral routes such as transdermal patch or cream.

Acne and hair growth were more common with testosterone. The authors reported no serious adverse events in the included trials and concluded that non-oral routes are preferred because of a neutral lipid profile.

The ISSWSH 2021 clinical practice guideline (Parish et al.) builds a practice path on that consensus: systemic transdermal testosterone for postmenopausal women with HSDD not primarily driven by modifiable relationship or mental-health factors, after informed consent that names off-label use in the United States.

ISSWSH states that a total testosterone level should not diagnose HSDD, but should serve as a baseline for monitoring, and that levels should stay in the physiologic premenopausal range.

What does the evidence not support?

Global Consensus is explicit about non-indications. It finds insufficient evidence to support testosterone to improve cognitive performance or delay cognitive decline. Available data show no effect on general wellbeing in postmenopausal women and no demonstrated effect on depressed mood. Musculoskeletal data are limited; available results do not support an effect on spine, total hip, or femoral neck bone mineral density at 12 months, and no clear effect on lean mass, total body fat, or muscle strength at physiologic doses. The consensus also states there are insufficient data to recommend testosterone for premenopausal women for sexual function or any other outcome.

FDA's Federal Register background likewise states that beyond HSDD, data on treatment effects for other clinical uses are limited.

On breast cancer, Global Consensus notes that women with prior breast cancer were excluded from the HSDD randomized trials and recommends caution in women with hormone-sensitive breast cancer. Long-term breast safety remains a named FDA knowledge gap, not a settled all-clear.

What is known about cardiovascular safety?

Long-term cardiovascular safety remains uncertain. The Global Consensus statement says physiologic-dose safety data are unavailable beyond 24 months and that trial findings do not generalize to women at high cardiometabolic risk.

Islam et al. (2019) reported no serious adverse events in the included trials, which were mostly short-term and were not long-term cardiovascular outcome studies. Global Consensus states that recommendations on physiologic testosterone and cardiovascular health are not generalizable to higher-risk populations or to long-term therapy, that oral testosterone is not recommended because of adverse lipid effects, and that safety data for physiologic doses are not available beyond 24 months. An absence of serious adverse events in short-term trials does not establish long-term cardiovascular safety.

Agrawal et al. (2024), a peer-reviewed TriNetX claims-database study, reported lower MACE risk overall among adult women with at least three systemic testosterone prescriptions in a year (RR 0.64; 95% CI 0.51 to 0.81). In women aged 56 and older, the MACE estimate was not significantly different from matched controls (RR 0.84; 95% CI 0.64 to 1.10). This observational association does not establish causation or resolve long-term safety for an individual patient.

What should you document if you prescribe off label?

Document the HSDD assessment, off-label consent, baseline and follow-up testosterone levels, formulation, and dated safety discussion. The checklist below follows Global Consensus and ISSWSH where those sources give practice language and does not replace state medical board rules or pharmacy law.

1. Indication. Document HSDD after a biopsychosocial assessment. Global Consensus says this is the only evidence-based indication. Do not chart testosterone for "energy," "brain fog," "weight," or "bone" as if those were proven indications.
2. Off-label consent. ISSWSH directs clinicians to obtain informed consent and to discuss off-label use, benefits, risks, and alternatives. Name the absence of an FDA-approved female product in the United States.
3. Baseline labs. Measure total testosterone before starting, as a baseline for monitoring, not as a diagnostic test for HSDD (ISSWSH). Global Consensus and ISSWSH both warn that many direct assays are unreliable in the female range; use a laboratory method appropriate for female concentrations when you can.
4. Target range and follow-up levels. Keep concentrations in the physiologic premenopausal or female range. Global Consensus advises a repeat total testosterone 3 to 6 weeks after starting to check for overuse. ISSWSH describes monitoring for androgen excess and for levels that stay physiologic. If there is no benefit by 6 months, Global Consensus says treatment should be stopped.
5. Formulation caution. Global Consensus advises against compounded "bioidentical" testosterone for HSDD because efficacy and safety evidence is lacking, with a limited exception when an authorized equivalent is unavailable. ISSWSH does not recommend compounded testosterone; it also notes quality standards if a compounded product is nevertheless used. They also advise against pellets and injections that drive supraphysiologic concentrations. Where no approved female product exists, Global Consensus says off-label use of an approved male formulation can be reasonable if blood levels stay in the physiologic female range. ISSWSH describes cautious use of approximately one-tenth of a standard male transdermal dose when a female formulation is unavailable. Applied gel dose and the amount delivered by a patch are different measures and should not be treated as interchangeable. Treat that as guideline context, not as a universal dose for every product and every patient. Prefer non-oral routes when lipid neutrality matters, per Islam 2019. For broader compounding, telehealth, and licensure context, Scriptura’s state-by-state prescribing reference links to official sources; check the current state and federal requirements for the specific prescription.

6. Safety discussion dated to October 2026. Document the individual benefit–risk discussion, including the short-term RCT safety picture, the Global Consensus 24-month evidence limit, and FDA's named cardiovascular and breast safety knowledge gaps.

Expert clinician perspectives and case examples

Jennifer Gibbons, FNP-C

Chief Medical Officer and Head of Clinical Operations

Root Rx Health

“I think with the right provider, the proper monitoring and realistic expectations, women can greatly benefit from testosterone, supplementation and optimization.”

Clinical history

Gibbons describes a 52-year-old woman with no reported prior medical conditions, medications or allergies. She reported night sweats, moodiness, lethargy, difficulty staying asleep and difficulty building muscle despite regular exercise. Her chief concern was social withdrawal after previously enjoying being around others.

Evaluation, treatment and follow-up

Gibbons reports an initial total testosterone of 7 ng/dL. The patient was concerned about long-term testosterone use and preferred to avoid injections. Taking her symptoms and treatment preferences into account, Gibbons recommended a cream combining progesterone, estrogen and testosterone. At six months, she reports total testosterone of 26 ng/dL and the patient describing less irritability and renewed motivation to be around other people.

How her practice is evolving

In a separate update on her practice, Gibbons says she now requires DUTCH Complete testing for her hormone patients to understand how they metabolize hormones, with the aim of individualizing treatment more safely. She also reports that a liposomal testosterone option was recently added to the formulary. She has not yet used it and intends to do so.

Evidence context

This is one practitioner’s account of three-hormone treatment, so the reported response cannot be attributed to testosterone alone. The 2019 Global Consensus Position Statement supports assessed postmenopausal HSDD as the only evidence-based indication, rather than broad wellbeing benefits. The 2021 ISSWSH guideline recommends serum testosterone monitoring within the physiologic premenopausal range; long-term safety remains unestablished. The DUTCH method-comparison study tested urine-measurement agreement, not whether test-guided care improves outcomes or safety. In its compounded-bioidentical-hormone guidance, NAMS 2022 advises against urine testing to determine dosing.

Dr. Irina Patten, DACM, LAc, CFMP

Chief Clinical Officer, Scriptura Health

Dr. Patten’s Center for Holistic Wellness

Acupuncture | Functional Medicine | Genetics & Genomics

“While the strongest clinical evidence currently supports testosterone therapy for HSDD, I believe its potential benefits extend beyond sexual function and deserve further investigation.”

Clinical perspective

Dr. Patten describes a personalized, symptom-driven approach. She reports that women in her practice describe improvements in energy, motivation, mood and quality of life with individualized hormone therapy. These observations inform the questions she wants researchers to examine.

Evaluation and monitoring

Her approach considers total testosterone, SHBG, estradiol, thyroid function and metabolic health. She incorporates blood testing to assess circulating hormone levels and DUTCH testing to explore hormone metabolism and estrogen detoxification pathways. She also considers genetic variations affecting androgen signaling and hormone metabolism to further personalize care, while recognizing that genetic and DUTCH testing are not validated for determining testosterone dosing. She emphasizes physiological dosing, symptom assessment and regular monitoring.

Research context

Among the studies Dr Patten highlights, Glynne et al.'s pilot study followed 510 women already using menopausal hormone therapy and reported improvements in self-reported mood and cognitive symptoms after testosterone was added. Its retrospective, uncontrolled design cannot establish that testosterone caused those changes. Huang et al.'s randomized dose-response trial in hysterectomized women receiving estradiol found body-composition and muscle-performance effects, but significant gains over placebo occurred at the highest dose, which produced supraphysiologic testosterone levels. These findings support further investigation; they do not establish routine treatment for energy, mood, cognition or muscle health at physiologic female doses. The Global Consensus Position Statement continues to identify assessed postmenopausal HSDD as the evidence-based indication.

Clinician Case Example: How One Physician Approaches Testosterone for Women

Agnes Usoro, MD

Physician-Owner & Medical Director

Scriptura Clinical Council Member

River Oaks Galleria Medspa

This describes one clinician’s practice for educational purposes. It is not dosing guidance; treatment decisions belong with your own clinician.

Clinical perspective

Dr. Usoro considers testosterone for appropriately selected perimenopausal and postmenopausal women. She notes that the strongest evidence supports its use for hypoactive sexual desire disorder (HSDD). In her practice, patients have reported improvements in energy, mental clarity, body composition when combined with resistance training, and quality of life. She stresses that the literature does not consistently show benefits for cognition, fatigue, muscle mass or weight, so she does not present these as established indications.

Evaluation and monitoring

Her workup is comprehensive and also considers estrogen. She monitors baseline testosterone, cardiovascular and metabolic risk, and androgenic side effects. In her own practice, she generally aims for total testosterone of 80 to 120 ng/dL and free testosterone above 15 ng/dL [unit to be confirmed with Dr. Usoro], but she ultimately targets symptom resolution rather than an exact number. She doses based on weight in kilograms and percent body fat, with a body composition scan before each quarterly pellet insertion.

Counseling

She counsels patients on acne, hirsutism and hair loss, and on the limits of the long-term cardiovascular and breast safety data. She also emphasizes that “bioidentical” does not automatically mean safer or more effective.

How can clinicians comment on FDA docket FDA-2026-N-5479?

FDA opened docket FDA-2026-N-5479 with the workshop notice. Per the FDA workshop page and the Federal Register ADDRESSES section, electronic comments through regulations.gov are accepted until 11:59 p.m. Eastern Time on October 19, 2026. Late comments will not be considered. The Federal Register API lists the direct comment link as https://www.regulations.gov/commenton/FDA-2026-N-5479-0001.

You can also open https://www.regulations.gov/docket/FDA-2026-N-5479 and follow the site's Submit Comment instructions. Written/paper comments go to FDA Dockets Management Staff (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, and must include Docket No. FDA-2026-N-5479. Comments become public, so strip confidential patient identifiers. A GovInfo PDF of the notice is available if the web page is hard to load.

Useful comment content for clinicians: how you diagnose HSDD, how you keep levels in the female range, which formulations you see in practice, adverse events you have or have not observed, and which long-term cardiovascular and breast endpoints you believe a development program must measure. FDA asked for broad public comment on risks and benefits related to testosterone use in menopausal women.

Where does Scriptura fit?

When a patient asks whether testosterone can help low libido or fatigue, the clinician needs the indication boundary, the lab and consent trail, and the dated regulatory record in one place. Scriptura is clinical decision-support software for licensed practitioners. It is built to bring source-linked evidence and documentation prompts into a clinician-reviewable plan. You review, edit, and sign every plan. Scriptura does not diagnose or prescribe, and it does not create an FDA-approved female testosterone product. Clinicians who want to help review specialty protocols and evidence gaps can explore Scriptura’s Clinical Council and discuss whether an advisory contribution is a mutual fit. If you want to see how an HSDD-focused, source-linked check lands in a chart, book a Scriptura demo.

Planning capacity for broader perimenopause and menopause care? Use Scriptura’s Physician ROI Calculator to explore clinician time, staff workload, and follow-up revenue with your own practice assumptions, treating the outputs as scenarios rather than guaranteed results.

Book a Scriptura demo

Key takeaways

• Evidence-based use in postmenopausal women is HSDD after biopsychosocial assessment, at physiologic female-range doses (Global Consensus 2019; Islam 2019; ISSWSH 2021).
• Evidence does not support testosterone as proven therapy for fatigue, memory loss, weight gain, bone density, cognition, or general wellbeing.
• No FDA-approved testosterone product exists for U.S. women; prescribing remains off label.
• Long-term cardiovascular safety remains unresolved; Global Consensus notes a lack of physiologic-dose safety data beyond 24 months.
• FDA docket FDA-2026-N-5479 accepts comments through 11:59 p.m. ET October 19, 2026.

Frequently asked questions

About the author

Related articles

Broader reading on evidence appraisal, regulatory monitoring, and clinician-led review:

• How to stay current without reading hundreds of PubMed papers: evaluating new research and tracing recommendations to sources.
• Why regulations are changing faster than clinics realize: monitoring FDA, compounding, and state-rule changes.
• The visit should start before the patient walks in: gathering patient history and lab context for clinician review.

Reference resources: Clinician Reference Library and Scriptura Therapeutics Library.

Get clinical evidence updates: subscribe to Scriptura Clinical Intelligence.

Sources

1. Global Consensus Position Statement (2019)
2. Islam et al. systematic review and meta-analysis (2019)
3. ISSWSH clinical practice guideline (2021)
4. Agrawal et al. claims-database analysis (2024)
5. FDA workshop and comment-docket notice (2026)